Chemogenetic activation of locus coeruleus neurons ameliorates the severity of multiple sclerosis.

ABSTRACT:

Background

Most current disease-modifying therapies approved for multiple sclerosis (MS) are immunomodulatory drugs that counteract the aberrant activity of the immune system. Hence, new pharmacological interventions that drive anti-inflammatory activity and neuroprotection would represent interesting alternative therapeutic approaches or complementary strategies to treat progressive forms of MS. There is evidence of reduced noradrenaline levels and alterations to locus coeruleus (LC) noradrenergic neurons in MS patients, as well as in animal models of this disease, potentially factors contributing to the pathophysiology. Drugs that enhance noradrenaline appear to have some beneficial effects in MS, suggesting their potential to dampen the underlying pathology and disease progressi

SUBMITTER: Torrillas-de la Cal A 

PROVIDER: S-EPMC10474779 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature